Kalaris Therapeutics Stock (NASDAQ:KLRS)


OwnershipChart

Previous Close

$2.76

52W Range

$2.28 - $24.15

50D Avg

$2.77

200D Avg

$8.96

Market Cap

$54.70M

Avg Vol (3M)

$49.95K

Beta

-

Div Yield

-

KLRS Company Profile


Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jul 30, 2020

Website

KLRS Performance


Latest Earnings Call Transcripts


Q4 12Mar 04, 13 | 5:00 PM
Q3 12Nov 14, 12 | 5:00 PM
Q2 12Aug 02, 12 | 5:00 PM